Metastatic castration-resistant prostate cancer Trials in Baltimore, United States
Conditions / Metastatic castration-resistant prostate cancer / Baltimore, United States
Metastatic castration-resistant prostate cancer has been the subject of sustained clinical investigation across multiple research sites.
31 total trials for this combination
Showing top 10 of 31 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT03845166 | A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors | ACTIVE_NOT_RECRUITING | PHASE1 |
| NCT05919264 | FOG-001 in Locally Advanced or Metastatic Solid Tumors | RECRUITING | — |
| NCT04925284 | Study of XB002 in Subjects With Solid Tumors (JEWEL-101) | COMPLETED | PHASE1 |
| NCT03829436 | TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers | COMPLETED | PHASE1 |
| NCT06764485 | A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer | RECRUITING | PHASE3 |
| NCT05519449 | Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01) | RECRUITING | PHASE1 |
| NCT04068896 | Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy | COMPLETED | PHASE1/PHASE2 |
| NCT04249947 | P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC) | TERMINATED | PHASE1 |
| NCT02952534 | A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency | COMPLETED | PHASE2 |
| NCT03454451 | CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers | COMPLETED | PHASE1 |